Literature DB >> 7949222

Transient neonatal diabetes mellitus: a relapse after 10 years of complete remission.

M Vanelli1, A De Fanti, S Cantoni, G Chiari.   

Abstract

The follow-up study of a patient with permanent diabetes (DM) unrelated to islet cell antibody and anti-insulin antibodies and occurring 10 years after a transient neonatal DM episode is reported. A latent defect in insulin release was proved. It produced transient glucosuria during intercurrent illnesses and permanent hyperglycaemia and a decrease in growth velocity [with high stimulated growth hormone and low insulin-like growth factor I (IGF-I)] at the onset of puberty. After insulin therapy was re-introduced, catch-up growth and normalization of the blood glucose and IGF-I levels were noted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7949222     DOI: 10.1007/bf00570547

Source DB:  PubMed          Journal:  Acta Diabetol        ISSN: 0940-5429            Impact factor:   4.280


  10 in total

1.  Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays.

Authors:  E Bonifacio; C Boitard; H Gleichmann; M A Shattock; J L Molenaar; G F Bottazzo
Journal:  Diabetologia       Date:  1990-12       Impact factor: 10.122

2.  Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement.

Authors:  C J Greenbaum; J P Palmer; B Kuglin; H Kolb
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

3.  Effect of diabetes and its control on insulin-like growth factors in the young subject with type I diabetes.

Authors:  S A Amiel; R S Sherwin; R L Hintz; J M Gertner; C M Press; W V Tamborlane
Journal:  Diabetes       Date:  1984-12       Impact factor: 9.461

4.  Congenital absence of islets of Langerhans.

Authors:  J A Dodge; K M Laurence
Journal:  Arch Dis Child       Date:  1977-05       Impact factor: 3.791

5.  Congenital pancreatic hypoplasia: a syndrome of exocrine and endocrine pancreatic insufficiency.

Authors:  W E Winter; N K Maclaren; W J Riley; P P Toskes; J Andres; A L Rosenbloom
Journal:  J Pediatr       Date:  1986-09       Impact factor: 4.406

6.  Recurrence of insulin-dependent diabetes mellitus after transient neonatal diabetes: a report of two cases.

Authors:  D Weimerskirch; D J Klein
Journal:  J Pediatr       Date:  1993-04       Impact factor: 4.406

Review 7.  Insulin as a growth factor.

Authors:  D J Hill; R D Milner
Journal:  Pediatr Res       Date:  1985-09       Impact factor: 3.756

8.  Clinical data regarding the growth of diabetic children.

Authors:  M Vanelli; A de Fanti; B Adinolfi; L Ghizzoni
Journal:  Horm Res       Date:  1992

Review 9.  Permanent diabetes without serological evidence of autoimmunity after transient neonatal diabetes.

Authors:  M E Gottschalk; D A Schatz; M Clare-Salzler; D L Kaufman; G S Ting; M E Geffner
Journal:  Diabetes Care       Date:  1992-10       Impact factor: 19.112

10.  Effect of intensive insulin treatment on linear growth in the young diabetic patient.

Authors:  M C Rudolf; R S Sherwin; R Markowitz; S E Bates; M Genel; J Hochstadt; W V Tamborlane
Journal:  J Pediatr       Date:  1982-09       Impact factor: 4.406

  10 in total
  3 in total

1.  Aetiopathology and genetic basis of neonatal diabetes.

Authors:  J P Shield; R J Gardner; E J Wadsworth; M L Whiteford; R S James; D O Robinson; J D Baum; I K Temple
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-01       Impact factor: 5.747

2.  Permanent neonatal diabetes mellitus: epidemiology, mode of presentation, pathogenesis and growth.

Authors:  A T Soliman; M M elZalabany; B Bappal; I alSalmi; V de Silva; M Asfour
Journal:  Indian J Pediatr       Date:  1999 May-Jun       Impact factor: 1.967

Review 3.  Transient and permanent neonatal diabetes.

Authors:  S Fösel
Journal:  Eur J Pediatr       Date:  1995-12       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.